The Uro-GHD features a 1280x720 pixel sensor, a first in portable, single-use endoscopy. LOS ALTOS, CA / ACCESSWIRE / April 7, 2023 / UroViu Corp (www.uroviu.com) has launched the new Uro-GHD, a ...

Bladder biopsy of normal-looking mucosa, as determined by cystoscopy, might not add clinical value in patients with positive voided-urine cytology after treatment of non-muscle-invasive bladder cancer ...

Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...

SHANGHAI, Aug. 15, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of ...

UroViu Corporation, a company develops a suite of diagnostic and therapeutic endoscopic products, has announced that its Uro-V single-use diagnostic cystoscopic system has received 510(k) clearance ...

A cystoscopy is a test to check the health of your urethra and bladder. You might also hear it called a cystourethroscopy or, more simply, a bladder scope. It’s an outpatient test, which means you can ...

A cystoscopy is a procedure that involves inserting a tool into the urethra and up into the bladder to examine these organs. The tool is a cystoscope — a thin, flexible instrument with a light and a ...

LOS ALTOS, Calif.--(BUSINESS WIRE)--UroViu Corporation announced today that it has received CE certification for its cystoscope and hysteroscope product portfolio. This includes the reusable UV5000w ...

Cystoscopy without the aid of urinary markers is the most cost-effective strategy for detecting recurrence of non-invasive bladder cancer, according to researchers. In a study that examined five ...

SHANGHAI, Feb. 21, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of ...

In a trial, Xpert® Bladder Cancer Monitor, a non-invasive urinary biomarker test, appeared suitable for guiding cystoscopy during monitoring of patients with NMIBC. Alternating between cystoscopy and ...